DCAT Week
CordenPharma to Establish New Peptide Manufacturing Facility in Switzerland
This >€500 million investment will feature multiple manufacturing lines capable of supporting small, medium, and large-scale peptide production.
An aerial sketch of CordenPharma’s future peptide manufacturing facility in Muttenz, Switzerland. Image: CordenPharma.
As part of its growth initiatives, CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz, 8 km outside Basel—a major biotech and pharma hub within Europe.
Dr. Michael Quirmbach, President & CEO of CordenPharma Group, said: “We are excited to announce the construction of a state-of-the-art manufacturing plant just outside Basel, Switzerland, within one of the leading pharma and biotech hubs in Europe. The new facility is designed to deliver flexible and efficient peptide manufacturing to meet the growing demand of innovative peptide medicines for our customers and ultimately, patients.”
The plant’s location near Basel offers efficient infrastructure, optimal logistics, and access to a skilled workforce. Furthermore, the surrounding industrial park promotes sustainable operations with closed-loop systems and waste-to-value streams.
This >€500 million investment will feature multiple manufacturing lines capable of supporting small, medium, and large-scale peptide production with small- to large-scale Solid Phase Peptide Synthesis (SPPS) reactors for GLP-1 and non-GLP-1 peptide projects – with a total SPPS reactor capacity of more than 5,000 L. The new facility will feature advanced automation, cutting-edge digitalization, and innovative peptide production technologies, ensuring compliance with the most stringent regulations, including BLA requirements.
With the main construction and qualification phase taking place between 2025 and 2027 and the start of commercial activities to begin in the first half of 2028, the company expects to generate over 300 new jobs, contributing to economic growth and innovation of the region.
Once fully operational, the Switzerland site will significantly enhance the company’s production capabilities, solidifying CordenPharma’s position as one of the largest peptide manufacturing partners in the CDMO peptide space.
